Complex insertion/deletion polymorphism in NOD1 (CARD4) is not associated with inflammatory bowel disease susceptibility in East Anglia panel

Inflammatory Bowel Diseases

Volumn 12, Issue 10, 2006, Pages 967-971

  Tremelling, Mark ^a   Hancock, Laura ^b   Bredin, Francesca ^a   Sharpstone, Daniel ^c   Bingham, Shiela A ^d   Parkes, Miles ^a,e  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c WEST SUFFOLK HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Crohn's disease; Genetic association; Inflammatory bowel disease; NOD1 (CARD4); Ulcerative colitis

Indexed keywords

GENE PRODUCT; PROTEIN CARD4; PROTEIN NOD1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL HETEROGENEITY; COMPUTER PROGRAM; CONTROL GROUP; CONTROLLED STUDY; CROHN DISEASE; DATA ANALYSIS; ENTERITIS; FEMALE; GENE DELETION; GENE INSERTION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; LABORATORY DIAGNOSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; ULCERATIVE COLITIS; UNITED KINGDOM;

ADULT; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GREAT BRITAIN; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; NOD1 SIGNALING ADAPTOR PROTEIN; POLYMORPHISM, GENETIC;

EID: 33749324435     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.mib.0000234131.89971.e5     Document Type: Article

References (19)

1. McGovern DP, Hysi P, Ahmad T, et al. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet. 2005;14:1245-1250.
2. Satsangi J, Parkes M, Louis E, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet. 1996;14:199-202.
3. Cho JH, Nicolae DL, Gold LH, et al. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. PNAS. 1998;95:7502-7507.
4. Rioux JD, Silverberg MS, Daly MJ, et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet. 2000;66:1863-1870.
5. van Heel DA, Fisher SA, Kirby A, et al. Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum Mol Genet. 2004;13:763-770.
6. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603.
7. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
8. Tada H, Aiba S, Shibata K, et al. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect Immun. 2005;73:7967-7976.
9. Hysi P, Kabesch M, Moffatt MF, et al. NOD1 variation, immunoglobulin E and asthma. Hum Mol Genet. 2005;14:935-941.
10. Girardin SE, Jehanno M, Mengin-Lecreulx D, et al. Identification of the critical residues involved in peptidoglycan detection by Nod1. J Biol Chem. 2005;280:38648-38656.
11. Waller S, Tremelling M, Bredin F, et al. Evidence for association of OCTN genes and IBD5 with ulcerative colitis. Gut. 2006;55:809-814.
12. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6.
13. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohns's disease: report of the working party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8-15.
14. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ. 1995;310:170.
15. Chamaillard M, Hashimoto M, Horie Y, et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol. 2003;4:702-707.
16. Masumoto J, Yang K, Varambally S, et al. Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. J Exp Med. 2006;203:203-213.
17. Netea MG, Ferwerda G, de Jong DJ, et al. The frameshift mutation in Nod2 results in unresponsiveness not only to Nod2- but also Nod1-activating peptidoglycan agonists. J Biol Chem. 2005;280:35859-35867.
18. Daly MJ, Pearce AV, Farwell L, et al. Association of DLG5 R30Q variant with inflammatory bowel disease. Eur J Hum Genet. 2005;13:835-839.
19. Zouali H, Lesage S, Merlin F, et al. CARD4/NOD1 is not involved in inflammatory bowel disease. Gut. 2003;52:71-74.